BioCentury
ARTICLE | Company News

Oncology Venture gains rights to Topotarget's APO010

November 14, 2012 2:28 AM UTC

Newco Oncology Venture ApS (Copenhagen, Denmark) debuted on Tuesday and acquired exclusive, worldwide rights from Topotarget A/S (CSE:TOPO) to APO010, a recombinant fusion protein drug consisting of t...